Imipenem
Imipenem is one of the semisynthetic thienamycins with antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, which is stable to many beta-lactamases and shows a long half-life because of binding to plasma proteins [1].
Penicillin-binding proteins (PBPs) are a kind of membrane proteins, widely existing on the surface of bacteria, which is the main target site of beta-lactam antibiotics.
In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b [2]. The inhibition of PBPs reduces the number of peptidoglycan polymer in the bacterial cell, thus prevent the forming of the bacterial cell wall and lead to cell death [3].
Reference:
[1]. Zhanel G G, Wiebe R, Dilay L, et al. Comparative review of the carbapenems [J]. Drugs, 2007, 67(7): 1027-52.
[2]. Nicolau D P. Carbapenems: a potent class of antibiotics [J]. Expert Opin Pharmacother. 2008, 9(1): 23-37.
[3]. Brunton L L, Hilal-Dandan R, Knollmann B C. eds (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 299.35 |
| Cas No. | 64221-86-9 |
| Formula | C12H17N3O4S |
| Solubility | insoluble in EtOH; insoluble in DMSO; ≥29.9 mg/mL in H2O with gentle warming |
| Chemical Name | (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| SDF | Download SDF |
| Canonical SMILES | C[C@](O)([H])[C@](C1=O)([H])[C@@](N21)([H])CC(SCCNC=N)=C2C(O)=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Polymorphonuclear leucocytes (PMNs) and lymphomonocytes |
|
Reaction Conditions |
15, 30 and 60 mg/l imipenem |
|
Applications |
Preincubation of PMNs with the highest dosages (30 and 60 mg/l) was found to increase phagocytosis, while no effect was detected on superoxide anion production, as well as on lymphomonocyte proliferative response and cytokine production. |
| Animal experiment:[2] | |
|
Animal models |
Male Sprague-Dawley rats aged 8 ~ 10 weeks and weighing 150 ~ 250 g, subjected to cecal ligation and puncture (CLP) |
|
Dosage form |
120 mg/kg Injected intraperitoneally 6 h post-CLP and every 12 h for a total of 7 days |
|
Applications |
Imipenem combined with low-dose cyclophosphamide (CTX) could improve the survival rate of rats with sepsis compared with rats treated with imipenem alone. However, this combination significantly reduced IL-10 expression, potentially causing damage to the intestinal barrier function. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Pasqui AL, Di Renzo M, Bruni F, et al. Imipenem and immune response: in vitro and in vivo studies. Drugs under Experimental and Clinical Research, 1995, 21(1): 17-22. 2. Guo P, Zhang SW, Zhang J, et al. Effects of imipenem combined with low-dose cyclophosphamide on the intestinal barrier in septic rats. Experimental and Therapeutic Medicine, 2018, 16(3): 1919-1927. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
